Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, Viking Therapeutics aims to advance novel treatments that address significant unmet medical needs. The company’s mission is to improve the lives of patients by harnessing the power of its proprietary drug development platforms.
Viking Therapeutics is particularly known for its work on therapies for conditions such as non-alcoholic steatohepatitis (NASH), obesity, and other metabolic diseases. The company’s lead product candidate, VK2809, is a novel, oral therapy designed to treat NASH and other indications related to lipid metabolism. Viking is also exploring additional candidates that target metabolic and hormonal pathways, which have the potential to provide substantial benefits over existing treatments.
The main drivers of growth for Viking Therapeutics include the increasing prevalence of metabolic disorders, coupled with a growing recognition of the need for effective therapies. As the global obesity epidemic continues to rise and conditions like NASH gain more attention, Viking’s innovative drug candidates are well-positioned to capitalize on these trends. Additionally, the company’s focus on research and development, strategic collaborations, and potential partnerships with larger pharmaceutical companies enhance its ability to bring new therapies to market and secure funding for ongoing clinical trials. Viking Therapeutics’ commitment to advancing science and improving patient outcomes supports its long-term growth potential in the biopharmaceutical industry. Learn more at Viking Therapeutics, Inc..
Click The Image For Current Live Chart